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Treatment-emergent endocrine symptoms and the risk of 
breast cancer recurrence: a retrospective analysis of the 
ATAC trial
Jack Cuzick, Ivana Sestak, David Cella, Lesley Fallowﬁ eld, on behalf of the ATAC Trialists’ Group*
Summary 
Background When the mechanism of action behind treatment toxicity reﬂ ects the intended eﬀ ect on the treatment 
target, the toxicity might be a useful marker for eﬃ  cacy. During endocrine treatment of breast cancer, the occurrence 
of symptoms related to oestrogen depletion or oestrogen blockade might thus be a predictor of treatment eﬀ ectiveness. 
In this retrospective analysis, the relation between the reported incidence of vasomotor or joint symptoms and breast 
cancer recurrence in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial is assessed.
Methods Women with hormone-receptor-positive tumours who reported vasomotor or joint symptoms at the ﬁ rst 
follow-up visit (3 months) in the ATAC trial, (which assessed tamoxifen or anastrozole for adjuvant treatment of 
postmenopausal breast cancer), were compared with women without these symptoms to see if there was a relation 
between these symptoms and subsequent recurrence. The ATAC trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN18233230.
Findings 1486 of 3964 (37·5%) eligible women reported newly emergent vasomotor symptoms at the 3-month follow-
up visit and had lower subsequent recurrence than those who did not report these symptoms (223 during 
10 752 women-years of follow-up vs 366 during 11 573 woman-years of follow-up, respectively; hazard ratio [HR] 
0·84 [95% CI 0·71–1·00], p=0·04; adjusted for age, body-mass index, previous hormone-replacement therapy, nodal 
status, tumour size, and tumour grade). A greater decrease in breast-cancer recurrence was seen for the 1245 of 3964 
(31·4%) eligible women who reported new joint symptoms at the 3-month follow-up visit compared with those not 
reporting these symptoms (158 during 9242 women-years of follow-up vs 366 during 11 573 women-years of follow-
up; adjusted HR 0·60 [0·50–0·72], p<0·0001).
Interpretation The appearance of new vasomotor symptoms or joint symptoms within the ﬁ rst 3 months of treatment 
is a useful biomarker, suggesting a greater response to endocrine treatment compared with women without these 
symptoms. Awareness of the relation between early treatment-emergent symptoms and beneﬁ cial response to therapy 
might be useful when reassuring patients who present with them, and might help to improve long-term treatment 
adherence when symptoms cannot be alleviated eﬀ ectively.
Funding Cancer Research UK and AstraZeneca.
Introduction
Side-eﬀ ects often limit the dose of drugs that can be 
delivered, especially for cytotoxic chemotherapy where 
bone marrow, neurological, or gastrointestinal toxic 
eﬀ ects sometimes limit the achievable dose. These side-
eﬀ ects are usually not directly related to drug eﬀ ective-
ness, but determine the amount of drug that can be 
reasonably tolerated by patients. However, in a few cases, 
the occurrence of a speciﬁ c side-eﬀ ect can also predict 
the likelihood of treatment success. For example, the 
occurrence of graft-versus-host disease in patients 
receiving allogeneic bone-marrow transplantation for 
haematological malignancies predicts overall survival.1–4 
The occurrence of an acnei-form skin rash during the 
use of epidermal growth factor receptor (EGFR) 
antibodies (eg, cetuximab, panitumumab, or matu-
zumab), and also the kinase inhibitors, geﬁ tinib and 
erlotinib, is another example where a side-eﬀ ect is 
associated with a higher probability of treatment 
response.5,6 Side-eﬀ ects triggered by the therapeutic 
mechanism of action can be dose-independent. For 
example, in hormone therapy for breast cancer, neither 
tamoxifen nor aromatase inhibitors have a steep 
dose–response curve for either side-eﬀ ects or eﬃ  cacy.7,8 
The appearance of vasomotor symptoms or joint 
symptoms is more likely to be related to the individual 
response to these drugs than to the dose.
Vasomotor symptoms (eg, hot ﬂ ushes, night sweats, 
and cold sweats) are common side-eﬀ ects of endo-
crine treatment in women with early breast cancer.9 
Additionally, treatment with aromatase inhibitors in-
creases the incidence of arthralgia and other joint sym-
ptoms.10–12 For tamoxifen, there have been a few reports 
that women who developed vasomotor symptoms13–16 had 
a lower risk of breast cancer recurrence than those who 
did not have these side-eﬀ ects, but no data on vasomotor 
symptoms exist for aromatase inhibitors. Additionally, 
the incidence of joint symptoms is increased by all three 
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third-generation aromatase inhibitors (anastrozole, 
letrozole, and exemestane), and is probably, at least partly, 
the result of the profound decrease in oestrogen 
concentrations.10,17–19 However, to our knowledge, no 
associ ation between the development of joint symptoms 
and breast cancer recurrence has been reported.
Here, we investigate whether the early occurrence of 
endocrine symptoms (speciﬁ cally vasomotor symptoms 
or joint symptoms) is associated with treatment eﬃ  cacy. 
These symptoms are likely to be related to underlying 
genetic mechanisms involving drug metabolism or end-
organ response, which determine the eﬀ ective drug dose. 
Thus, the occurrence of certain symptoms could be 
the ultimate bioassay, which might be a reﬂ ection of the 
degree of biologically relevant oestrogen suppression 
produced in individual women by a speciﬁ c treatment.
Methods
The Arimidex, Tamoxifen, Alone or in Combination 
(ATAC) study was a double-blind randomised clinical 
trial in which postmenopausal women with histologically 
conﬁ rmed localised breast cancer were randomly 
assigned to receive daily anastrozole (1 mg) alone, 
tamoxifen (20 mg) alone, or the combination in a 
double blind, method for 5 years as adjuvant treatment. 
9366 women were randomised; 3125 were assigned 
anastrozole alone, 3116 were assigned tamoxifen alone, 
and 3125 were assigned the combination. Details of trial 
design, methods, and primary objectives have been 
published elsewhere.9 After the initial analysis at 
33 months of follow-up,9 the combination group was 
stopped because no beneﬁ t compared with tamoxifen 
alone was seen, in terms of either eﬃ  cacy or tolerability, 
and follow-up data were not subsequently collected. 
Therefore, our current analysis does not include these 
women and ﬁ ndings will be presented only for the 
monotherapy groups, with focus on women who started 
their initial therapy, who had a hormone-receptor-
positive tumour (oestrogen-receptor positive or pro-
gesterone-receptor positive or both positive), and who 
did not report vasomotor symptoms or joint symptoms 
at entry. Vasomotor symptoms were deﬁ ned as hot 
ﬂ ushes, night sweats, or cold sweats and joint symptoms 
included reports of arthralgia, arthritis, arthrosis, or 
joint disorder. Somewhat unconventionally, vasomotor 
and joint symptoms will be referred to together as 
endocrine symptoms, because both are related to a 
decrease in oestrogen concentrations. All side-eﬀ ects 
data were obtained from elicited responses regarding 
side-eﬀ ects, and a speciﬁ c symptom checklist was not 
used. All reports were reviewed by the trial medical 
oﬃ  cer, who was blinded to treatment allocation, to 
resolve any uncertain reports. Most symptoms occur 
soon after women start endocrine treatment,20,21 so we 
used the recording of these symptoms (all severities) at 
the initial 3-month follow-up visit as our measure of 
symptom occurrence. Endpoints for this retrospective 
analysis were recurrences occurring after the 3-month 
follow-up visit, so that they were subsequent to symptom 
reports. Symptoms reported after 3-months of initiation 
of the study therapy are not included in this analysis.
Regulatory and ethics authorities for all participating 
centres in 21 countries approved the protocol before 
enrolment of participants. The trial was done in 
accordance with the Declaration of Helsinki (1996 
revision) and under the principles of good clinical practice. 
The ATAC trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN18233230. 
Statistical analysis
The rate of breast cancer recurrence was calculated by 
dividing the number of observed events by the number 
of woman-years of follow-up for each group. Follow-up 
accrued until a breast cancer recurrence, death, or the 
cut-oﬀ  date for this analysis (March 31, 2007), which 
was the same as for the most recent 100-month follow-
up analysis.11 Odds ratios (OR) were used to compare 
factors aﬀ ecting the occurrence of vasomotor symptoms 
or joint symptoms at the 3-month visit. For the post-
 3-month period, hazard ratios (HR) and corresponding 
95% CIs were estimated by the proportional hazards 
regression model, both with and without adjustment 
for age, body-mass index (BMI), previous use of 
hormone replacement therapy (HRT), nodal status, 
tumour size, and tumour grade.22 Time-to-recurrence 
curves were formed by use of the Kaplan-Meier 
method.23 All p values are two-sided. All calculations 
were done by use of STATA, version 9.2.
Role of the funding source
The authors were responsible for data interpretation and 
writing the report. IS and JC had full access to the data and 
had joint decision with the Steering Committee to submit 
for publication. The commercial sponsor was represented 
in a minority on the Steering Committee (2 of 28). Astra-
Zeneca was responsible for all data collection, but this was 
done blinded to treatment allocation, which was held by 
the independent trial statistician. The sponsor was not 
involved in the study design, analysis, inter pretation of the 
data, or in writing the report. 
Results 
Overall, 590 of 6186 women (9·5%) who started treat ment 
had vasomotor symptoms and 577 women (9·3%) had 
joint symptoms at baseline (table 1). The size of these 
groups was small so subsequent recurrences were few 
(four women with vasomotor symptoms and three women 
with joint symptoms), but were not signiﬁ cantly diﬀ erent 
from those in patients who did not report baseline 
symptoms (vasomotor symptoms: HR 0·92 [95% CI 
0·29–5·9], p=0·7; joint symptoms: 0·68 [0·16–2·86], 
p=0·6). Women with baseline symptoms tended to report 
fewer new endocrine symptoms during the trial than 
those without baseline symptoms (data not shown).
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Women with hormone-receptor-negative tumours or 
with unknown hormone-receptor status and those with 
pre-existing vasomotor symptoms or joint symptoms at 
entry were excluded from the main analysis, leaving 
1967 women in the anastrozole group (13 824 woman-
years) and 1997 in the tamoxifen group (13 637 woman-
years; table 1). Mean age at entry was 63·9 years (SD 9·0) 
and 1590 of 3964 (40·1%) had previously received HRT. 
Detailed baseline characteristics have been published 
elsewhere.9  
Table 2 presents treatment-emergent side-eﬀ ects 
newly reported at the 3-month follow-up visit. 676 of 
1967 women (34·4%) in the anastrozole group reported 
vasomotor symptoms (with or without joint symptoms) 
compared with 810 of 1997 (40·1%) in the tamoxifen 
group (OR 0·77 [95% CI 0·67–0·87], p=0·0001). In the 
anastrozole group, 665 of 1967 women (33·8%) reported 
joint symptoms (with or without vasomotor symptoms) 
compared with 580 of 1997 (29·0%) in the tamoxifen 
group (OR 1·25 [1·09–1·43], p=0·001). More patients in 
the tamoxifen group reported vasomotor symptoms, 
whereas more patients in the anastrozole group 
reported joint symptoms, leading to a similar overall 
percentage of women reporting at least one of these 
symptoms (55% in both groups; 1092 of 1967 in the 
tamoxifen group vs 1096 of 1997 in the anastrozole 
group).  
After adjustment for age, BMI, previous HRT use, 
nodal status, tumour size, and tumour grade, women in 
the study population who reported vasomotor symptoms 
(with or without joint symptoms) at the 3-month follow-
up visit had fewer breast cancer recurrences than those 
who did not report these symptoms (HR 0·84 [95% CI 
0·71–1·00], p=0·04; table 3). Those reporting only 
vasomotor symptoms, but not joint symptoms, had a 
similar decrease in recurrence rates to those reporting 
vasomotor stymptoms with or without joint symptoms 
(not signiﬁ cant; table 3). The decrease in recurrence rates 
were similar in patients treated with either anastrozole or 
tamoxifen (table 3). 
The decrease in breast cancer recurrences for those 
reporting vasomotor or joint symptoms was equally 
clear for patients with local or distant recurrences. 
There was no evidence of heterogeneity for vaso-
motor symptoms (local recurrence: HR 0·80 [95% CI 
0·57–1·12]; distant recurrence: 0·83 [0·68–1·02]; 
pheterogeneity=0·5) or joint symptoms (local recurrence: 
HR 0·64 [0·45–0·91]; distant recurrence: 0·60 
[0·48–0·74]; pheterogeneity=0·3).  
The eﬀ ect size for vasomotor symptoms (with or 
without joint symptoms) was larger in an unadjusted 
analysis (HR 0·75 [95% CI 0·63–0·91], p=0·003), and of 
the adjustment factors, only previous HRT use was a 
signiﬁ cant confounding factor. For those without 
previous HRT use, the eﬀ ect of vasomotor symptoms on 
subsequent recurrence was small (HR 0·93 [0·77–1·13], 
p=0·5) and similar in both treatment groups (anastro-
zole group: HR 0·91 [0·68–1·22]; tamoxifen group: 
0·93 [0·72–1·20]). For those with previous HRT use, the 
eﬀ ect was substantially larger (HR 0·63 [0·46–0·85], 
p=0·003) and apparent in both treatment groups 
(anastrozole group: HR 0·53 [0·31–0·88]; tamoxifen 
group: 0·66 [0·45–0·96]). There was evidence for 
heterogeneity between those previously using HRT and 
those not (p=0·04), but not between treatment groups. 
Signiﬁ cantly fewer women in the study population 
reporting joint symptoms (with or without vasomotor 
symptoms) at the 3-month follow-up visit had a 
recurrence of breast cancer than those not reporting 
these symptoms (HR 0·60 [95% CI 0·50–0·72], 
p<0·0001; table 3). Findings were similar in an 
unadjusted analysis (0·54 [0·40–0·71]); no factor 
assessed seemed to confound the relation. Figure 1 
presents the recurrence proportion as a function of 
follow-up time according to treatment group and joint 
symptoms at the 3-month follow-up visit. The noted 
decrease was very similar in both treatment groups 
(table 3) and for women using previous HRT or not 
 Anastrozole Tamoxifen 
All randomised women, n 3125 3116
Exclusions, n (%)
Did not start randomised treatment 33 (1·1) 22 (0·7)
Hormone-receptor negative or unknown 
status
502 (16·1) 512 (16·4)
Joint symptoms only at baseline 303 (9·7) 274 (8·8)
Vasomotor symptoms only at baseline 300 (9·6) 290 (9·3)
Both side-eﬀ ects at baseline 20 (0·6) 21 (0·7)
Study population* 1967 1997
*Started allocated treatment, hormone-receptor positive, and no endocrine 
symptoms reported at trial entry.
Table 1: Exclusions from the randomised population by treatment group 
to obtain the study population
Patients
Anastrozole
No symptoms 875 (44·5)
Joint symptoms only 416 (21·1)
Vasomotor symptoms only 427 (21·7)
Both symptoms 249 (12·7)
Tamoxifen
No symptoms 901 (45·1)
Joint symptoms only 286 (14·3)
Vasomotor symptoms only 516 (25·8)
Both symptoms 294 (14·7)
Data are n (%).
Table 2: Women with hormone-receptor-positive tumours and who 
did not report either symptom at trial entry with vasomotor symptoms 
or joint symptoms at the 3-month follow-up visit according to 
treatment group
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(data not shown). Similar outcomes were seen if ﬁ ndings 
were restricted to women only reporting joint symptoms, 
but not vasomotor symptoms (table 3). 
Overall, the decrease in recurrence was greater for 
women reporting joint symptoms only compared with 
women with vasomotor symptoms only (table 3 and 
ﬁ gure 2). Women reporting either side-eﬀ ect had a 
signiﬁ cant decrease in recurrence compared with those 
reporting neither symptom (table 3). The decrease was 
again similar in both treatment groups (table 3). For 
women reporting both side-eﬀ ects at the 3-month follow-
up visit, a signiﬁ cantly greater decrease in breast cancer 
recurrence was noted compared with those not reporting 
any of these symptoms (table 3 and ﬁ gure 2). 
Figure 2 presents the proportion of patients with 
recurrence according to endocrine symptoms reported. 
Compared with women who reported neither symptom 
at the 3-month follow-up visit, women who reported both 
side-eﬀ ects had an absolute decrease in recurrence of 
11·4% (95% CI 9·9–12·5) after 9 years of follow-up, those 
with joint symptoms only had a 10% (8·7–10·8) absolute 
decrease, those who reported either side-eﬀ ect had a 8% 
(8·2–8·0) absolute decrease, and those with vasomotor 
symptoms had only a 6% (6·2–7·2) absolute risk 
decrease.
Discussion
We present a retrospective analysis of the ATAC trial, 
assessing whether the occurrence of treatment-related 
symptoms (vasomotor symptoms or joint symptoms) is 
associated with breast cancer recurrence. Our ﬁ nd ings 
suggest that the emergence of either symptom is 
predictive of signiﬁ cantly lower recurrence in both 
tamoxifen-treated and anastrozole-treated patients. A 
signiﬁ cantly larger eﬀ ect was noted for joint symptoms, 
which was similar in all subgroups, whereas the eﬀ ect of 
vasomotor symptoms was smaller and of borderline 
signiﬁ cance overall. The diﬀ erence in recurrence in 
patients with vasomotor symptoms (with or without joint 
symptoms) was substantially decreased after adjustment 
for age, BMI, previous HRT, nodal status, tumour size, 
and tumour grade and was most apparent in women who 
had taken HRT before trial entry. These ﬁ ndings were 
unaﬀ ected by age, BMI, or tumour characteristics. 
Analyses were restricted to patients with hormone-
receptor-positive breast cancer, but similar ﬁ ndings were 
obtained if analyses were based on all eligible randomised 
patients (data not shown). 
The analysis showed no signiﬁ cant diﬀ erence in 
recurrence in women who reported these symptoms at 
entry into the trial compared with those who did not 
report symptoms at entry. This ﬁ nding adds weight to 
the interpretation of these data as reﬂ ecting a causal 
treatment–patient interaction and not just a patient’s 
predisposition to these endocrine symptoms in the 
 A: no joint symptoms
T: no joint symptoms
A: joint symptoms
T: joint symptoms
 Number at risk
 A: no joint symptoms 1302 1190 1083 909 643 199 
 T: no joint symptoms 1417 1273 1154 966 624 181 
 A: joint symptoms 665 646 615 545 376 114
 T: joint symptoms 580 563 523 460 333 96
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Figure 1: Breast cancer recurrence according to treatment group and whether joint symptoms (with or 
without vasomotor symptoms) were reported at the 3-month follow-up visit in women without endocrine 
symptoms at entry
A=anastrozole. T=tamoxifen.
Anastrozole (N=1967) Tamoxifen (N=1997) Overall (N=3964)
n/wy (annual rate*) HR† (95% CI) p value n/wy (annual rate*) HR† (95% CI) p value n/wy (annual rate*) HR† (95% CI) p value
Neither side-eﬀ ect 163/5782 (2·8) 1‡ ·· 203/5791 (3·5) 1‡ ·· 366/11 573 (3·2) 1‡ ··
Vasomotor symptoms (with or 
without joint symptoms)
83/4993 (1·7) 0·85 (0·65–1·11) 0·3 140/5759 (2·4) 0·81 (0·65–1·01) 0·06 223/10 752 (2·1) 0·84 (0·71–1·00) 0·04
Vasomotor symptoms only 58/3080 (1·9) 0·87 (0·63–1·22) 0·4 100/3564 (2·8) 0·82 (0·63–1·05) 0·12 158/6645 (2·4) 0·84 (0·68–1·03) 0·09
Joint symptoms (with or 
without vasomotor symptoms)
78/4962 (1·6) 0·65 (0·50–0·85) 0·001 80/4281 (1·9) 0·58 (0·45–0·74) <0·0001 158/9242 (1·7) 0·60 (0·50–0·72) <0·0001
Joint symptoms only 53/3050 (1·7) 0·65 (0·47–0·90) 0·009 40/2086 (1·9) 0·55 (0·39–0·78) 0·001 93/5136 (1·8) 0·59 (0·46–0·74) <0·0001
Either side-eﬀ ect 111/6130 (1·8) 0·79 (0·67–0·94) 0·006 140/5651 (2·5) 0·73 (0·62–0·87) 0·001 251/11 781 (2·1) 0·72 (0·60–0·85) <0·0001
Both side-eﬀ ects 25/1912 (1·3) 0·56 (0·37–0·87) 0·01 40/2195 (1·8) 0·52 (0·36–0·75) <0·0001 65/4107 (1·6) 0·53 (0·40–0·71) <0·0001
wy=woman years. HR=hazard ratio. *Annual breast cancer recurrence rate calculated by dividing number of observed events by number of woman-years of follow-up for each group. †HRs adjusted for age, 
body-mass index, previous use of hormone replacement therapy, nodal status, tumour size, and tumour grade. ‡Reference group.
Table 3: Breast cancer recurrence rate and adjusted hazard ratios for endocrine symptoms reported at the 3-month follow-up visit according to treatment group in women with 
hormone-receptor-positive tumours and not reporting either symptom at entry
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absence of treatment. Additionally, patients who reported 
symptoms at baseline had fewer subsequent reports of 
these symptoms, but this might reﬂ ect a reporting bias 
in favour of new versus continuing symptoms.
The eﬀ ect size was similar in both treatment groups, and 
an overall lower recurrence rate in patients assigned 
anastrozole compared with those assigned tamoxifen was 
apparent, regardless of whether symptoms were present or 
not. However, the size of the eﬀ ect of symptoms on 
recurrence was similar to, or larger than, the diﬀ erence 
between anastrozole and tamoxifen, supporting the 
importance of this ﬁ nding. A detailed symptom question-
naire was not used, so it is possible that a larger eﬀ ect might 
have been observed if details were fully recorded.
Because the study only included women who began their 
allocated treatment, and endocrine symptoms were 
measured at the ﬁ rst follow-up visit, reported adherence to 
treatment in the ﬁ rst 3-month period was high (3952 of 
3964 [99·7%]) and is unlikely to aﬀ ect the reports of these 
symptoms. Although one could argue that the appearance 
of symptoms could lead to lower subsequent adherence 
and lower eﬃ  cacy, the opposite was actually noted. Women 
reporting either symptom took 88% (1925 of 2188) of their 
prescribed treatment (up to recurrence) compared with 
84% (1492 of 1776) in those with neither symptom. It seems 
unlikely that these small diﬀ erences could explain the 
diﬀ erences in recurrences, but the reported diﬀ erences in 
adherence might reﬂ ect larger real diﬀ erences, which could 
confound our ﬁ ndings.
Additionally, the appearance of symptoms would lead 
to the use of medicines that could also decrease 
recurrence as an additional eﬀ ect. Details of aspirin and 
other non-steroidal anti-inﬂ ammatory drugs were not 
collected accurately, but use of cyclo-oxygenase-2 in-
hibitors was collected accurately and only 12% (476 of 
3964) of our study population used these drugs at any 
stage during the treatment. Usage was higher in patients 
who reported vasomotor or joint symptoms than those 
who did not report these symptoms (data not shown), but 
the HR for recurrence was unchanged if use of COX-2 
inhibitors was added to the model. Similarly, only 9% of 
our study population used a bisphosphonate, and again 
use was higher in those with endocrine symptoms (data 
not shown). For those with joint symptoms, the hazard 
ratio was only slightly changed (HR 0·59 [95% CI 
0·49–0·72]) if the use of either of these drugs was added 
to the model.
The correlation of side-eﬀ ects with response to 
treatment has been noted in a few other situations, 
notably graft-versus-host disease for allogeneic bone-
marrow transplantation and skin rash for antibodies 
directed at the EGFR or tyrosine-kinase inhibitors. 
However, this is the ﬁ rst example to our knowledge 
where side-eﬀ ects of relatively non-toxic drugs with ﬂ at 
dose–response curves (for both eﬃ  cacy and side-eﬀ ects) 
have been useful in predicting treatment response. This 
eﬀ ect is likely to be mediated by individual genetic 
diﬀ erences in drug metabolism or end-organ response, 
but this notion has yet to be fully elucidated. 
Goetz and colleagues13,14 assessed the polymorphisms of 
cytochrome P450 (CYP) 2D6 enzyme in postmenopausal 
women with breast cancer treated with tamoxifen. They 
showed that women with a wild-type genotype had a lower 
risk of disease relapse and a higher incidence of vasomotor 
symptoms than those without a wild-type genotype in 
CYP2D6. Researchers from the Italian Tamoxifen 
Prevention Trial assessed the frequency of the variants 
CYP2D6 (*4/*4) and noted that women who developed 
breast cancer on tamoxifen had a higher frequency in 
CYP2D6 *4/*4 than those without breast cancer.24 
Additionally, pharmacological interventions used in 
managing vasomotor symptoms—eg, the selective 
serotonin reuptake inhibitors—inhibit CYP2D6 and 
therefore decrease the eﬃ  cacy of tamoxifen. In our study, 
a relation between vasomotor symptoms and breast 
cancer recurrence was seen, not only for tamoxifen, but 
also for the aromatase inhibitor anastrozole, suggesting 
that factors other than the CYP2D6 polymorphism are 
also involved. One possibility is the CYP19 gene 
(aromatase) itself,25 but the full picture is likely to be more 
complicated and might involve other genetic loci.
This analysis supports an inverse association between 
the occurrence of vasomotor symptoms and breast cancer 
recurrence previously reported for tamoxifen,16 and 
extends this association to the aromatase inhibitor 
anastrozole and also to the presence of joint symptoms. 
Both of these symptoms are believed to be related to 
lowered oestrogen concentrations, although the speciﬁ c 
underlying cause of aromatase-inhibitor-induced joint 
symptoms is, as yet, unknown. In addition to stimulating 
Neither side-eﬀect
Vasomotor symptoms only
Either side-eﬀect
Joint symptoms only
Both side-eﬀects
 Number at risk
 Neither side-eﬀect 2017 1583 1416 1172 796 215 
 Vasomotor symptoms only 912 880 821 702 471 165 
 Either side-eﬀect 1947 1555 1449 1262 855 283
 Joint symptoms only 696 676 629 561 385 118
 Both side-eﬀects 539 533 509 444 324 92
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Figure 2: Breast cancer recurrence for anastrozole and tamoxifen treatments combined at diﬀ erent follow-up 
times according to endocrine symptoms reported at the 3-month follow-up visit in women with hormone-
receptor-positive tumours and without endocrine symptoms at entry
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further work in understanding the genetic basis for 
individual response to treatment, these ﬁ ndings also 
have important implications for communication between 
health-care professionals and patients with symptoms 
caused by endocrine therapy. Several reports26–28 have 
documented poor adherence to long-term endocrine 
therapy and an appreciation that endocrine symptoms 
indicate a stronger treatment eﬀ ect should help to 
encourage better symptomatic management and improve 
adherence for women receiving endocrine treatment. 
These ﬁ ndings also raise questions about the eﬀ ect that 
drugs aimed at ameliorating endocrine symptoms might 
have on the eﬃ  cacy of endocrine treatments, if they 
target the same mechanism of action.
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